Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers

Summary

This study investigates the initial safety profile of \[18F\]P16-129 in healthy volunteers including dosimetry determination, and compares the uptake and kinetics of \[18F\]P16-129 with the FDA approved drug \[18F\]florbetapir in the brains of Alzheimer's disease patients.

Timeline

Start

2018-02-21

Primary completion

2019-11-02

Completion

2019-11-02

Publications

• Alexoff D, Wong DF, Kuwabara H, Dannals RF, Ploessl K, Kung HF. Head to head comparison of two PET/CT imaging agents, [18F]D3FSP ([18F]P16-129) and [18F]AV45, in patients with alzheimer's disease. EJNMMI Res. 2025 Jun 22;15(1):77. doi: 10.1186/s13550-025-01276-w.

Drugs

Indications